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Background: There is an increasing focus on measuring patient-reported outcomes (PROs) as part of routine
medical practice, particularly in fields such as joint replacement surgery where pain relief and improvement in
health-related quality of life (HRQoL) are primary outcomes. Between-country comparisons of PROs may present
difficulties due to cultural differences and differences in the provision of health care. However, in order to understand
how these differences affect PROs, common predictors for poor and good outcomes need to be investigated. This
cross-sectional study investigates factors influencing health-related quality of life (HRQoL) one year after total hip
replacement (THR) surgery in Sweden and in Denmark.
Methods: Data was retrieved from the Swedish (n = 14 560 patients) and Danish (n = 632 patients) Hip Arthroplasty
Registers according to preset selection criteria. Using linear regression models, we examined how sex, age, comorbidity
and country of surgery were associated with different aspects of HRQoL as measured by the EQ-5D index and EQ VAS.
Results: Danish patients had an overall higher EQ-5D index and EQ VAS than Swedish patients (p < 0.001). After
regression analysis, the estimated coefficients for sex, age, or the Charlson score did not differ between countries for
either the EQ-5D index (p = 0.83) or EQ VAS (p = 0.41) one year after THR.
Conclusions: We conclude that there are clear similarities in how basic predictors influence patient-reported outcomes
(PROs) in patients with THR in Sweden and Denmark and these known predictors of good or poor HRQoL outcomes
are not specific for each country.
Keywords: Total hip replacement, EQ-5D, Predictors, Comorbidity, Patient-reported outcome, Patient-reported
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There is an increasing focus on measuring patient-
reported outcomes (PROs) as part of routine medical
practice, particularly in fields such as joint replacement
surgery where pain relief and improvement in health-
related quality of life (HRQoL) are primary outcomes.
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reproduction in any medium, provided the orpatient’s perspective. A commonly used instrument to
measure patient-reported health outcomes is the EQ-5D,
introduced by the EuroQol group in 1987. Health
outcomes according to EQ-5D have been found to differ
between European countries, calling for caution when
making international comparisons of disease burden and
health care effectiveness [1]. However, the differences in
the EQ-5D index have been found to be rather small re-
gardless of valuation method. Despite between-country
variations in the EQ-5D index, the associations between
age and sex and EQ-5D index was the same for all coun-
tries [2].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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toring, developing and improving joint replacement
surgery [3]. PRO measures are routinely collected for
all patients undergoing total hip replacement (THR) in
Sweden by the Swedish Hip Arthroplasty Register
(SHAR) [4]. In Denmark, occasional cross-sectional
collections of PROMs have been accomplished by the
Danish Hip Arthroplasty Register (DHR) in random
samples of the Danish THR population. Close collabor-
ation through the Nordic Arthroplasty Register Associ-
ation allows not only for pooling and comparisons of
national implant survival data, but also for analyses of
PROs.
The objective of this study was to investigate factors
predicting the level of HRQoL one year after THR in pa-
tients operated on in Denmark and Sweden. In particu-
lar we examined how sex, age, comorbidity and country
of surgery were associated with the EQ-5D index and
EQ VAS after surgery. We also investigated the external
validity of the results by comparing the associated vari-
ables between the two countries.
Methods
Study population
SHAR, started in 1979, and DHR, started in 1995, gather
prospective observational nationwide data. All public
and private orthopaedic departments performing THR
in Sweden and Denmark report to the respective regis-
ter. As part of a routine follow-up program, SHAR has
been collecting EQ-5D data since 2002. DHR has col-
lected EQ-5D data from a random subset of patients op-
erated in 1999, 2004 and 2008 [5].
For these analyses we selected THRs due to primary
osteoarthritis. From SHAR all patients operated in
2006 and 2007 and from DHR all patients operated in
2008 with complete one year EQ-5D data were in-
cluded. Patients re-operated within a year, or withTable 1 Characteristics of Swedish and Danish patients
Variable Denmark Sweden Danish
Male sex 40.5% (256) 42.2% (6148)
Age 68.5 (± 10.1) 69.4 (± 9.6)
Right side 54.6% (345) 56.1% (8174)
Year of surgery 2008.3 (± 0.2) 2007.0 (± 0.6)
Charlson score
Low 91.0% (575) 86.3% (12 561)
Medium (1–2) 8.4% (53) 12.8% (1859)
High (> 2) 0.6% (4) 1.0% (140)
Outcomes
EQ-5D 0.85 (± 0.19) 0.81 (± 0.19)
EQ-5D VAS 81.6 (± 19.5) 75.5 (± 20.4)
Data are presented as percentages (number of patients) for proportional variables,missing values in any of the outcome scores were ex-
cluded from the analysis. For bilateral cases the first
operation was selected.
Comorbidity profiles were estimated by cross-matching
data with the Swedish National Patient Register and the
Danish National Registry of Patients. Both Sweden and
Denmark have unique personal identification numbers
allowing a perfect match between registers. The disparity
in the choice of year for surgery was due to lack of comor-
bidity data from the Swedish National Patient Register at
the time the databases were merged. With these selection
criteria we identified 14 560 Swedish patients and 632
Danish patients.Outcomes variables
Patients selected for this study had completed a one year
follow-up EQ-5D questionnaire sent via ordinary mail.
The EQ-5D evaluates subjects in five HRQoL dimen-
sions, namely mobility, self-care, usual activities, pain/
discomfort and anxiety/depression [6,7]. In this version
of the EQ-5D instrument (EQ-5D-3L) each dimension is
divided into three levels of graded severity generating
243 possible response combinations. The EQ-5D can be
presented as a global health index with a weighted total
value for HRQoL. Due to the lack of a specific Swedish
EQ-5D tariff the Danish TTO tariff [8] was used for all
patients, ranging from −0.624 to 1, where 1 represents
the best possible health state. The EQ-5D also contains
a health state visual analogue scale (EQ VAS) ranging
from 0, worst imaginable health state, to 100, best im-
aginable health state.
The primary outcomes were the EQ-5D index and EQ
VAS one year after THR. Median time from surgery to
follow-up was 1.1 years (range 0.9-1.9) for the Swedish
population and 1.2 years (range 0.9-1.5) for the Danish
population.reference THR population Swedish reference THR population
43.8% (2579) 43.1% (10 182)
69.1 (± 9.8) 68.6 (± 10.3)
53.3% (3162) 55.5% (13 102)
(2008) (2006–2007)
89.7% (5318) 86.8% (20 481)
9.4% (557) 12.2% (2888)
1.0% (56) 1.0% (249)
- -
- -
while continuous variables are mean ±SD.
Table 2 Comparison of EQ-5D dimensions between Swed-
ish and Danish patients
Dimensions Denmark Sweden P-value
Mobility
No problems 79% (502) 59% (8603) < 0.001
Some problems 20% (129) 41% (5934)
Confined to bed 0% (1) 0% (20)
Self-care
No problems 88% (553) 91% (13 273) 0.0065
Some problems 12% (74) 8% (1187)
Unable 1% (5) 1% (96)
Usual activities
No problems 63% (397) 76% (10 997) < 0.001
Some problems 34% (212) 22% (3202)
Unable 4% (23) 2% (360)
Pain/discomfort
None 64% (406) 43% (6224) < 0.001
Moderate 33% (208) 53% (7662)
Extreme 3% (18) 5% (669)
Anxiety/depression
None 87% (549) 77% (11 200) < 0.001
Moderate 11% (71) 22% (3156)
Extreme 2% (12) 1% (199)
Data are presented as percentages (number of patients) and p-values are
derived from Fischer’s exact test.
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As independent possible predictors we investigated coun-
try, age at surgery, sex, and comorbidity as measured by
the Charlson comorbidity score. The Charlson comorbid-
ity score is a prospectively applicable method for classify-
ing co-morbid conditions which might alter the risk of
mortality. The Charlson score has 17 disease categories,
selected and weighted on the basis of the strength of
their association with mortality [9]. It is readily applic-
able in registry research and we used ICD-10 codes
(International Classification of Diseases version 10) forFigure 1 Comparison of factors influencing EQ-5D index between Sw
for the estimates of EQ-5D index one year after THR for gender (reference=
Charlson (reference=low Charlson) for Swedish (blue) and Danish (red) patiscore estimation [10] from hospitalizations one year prior
to surgery (including surgery hospitalization). Patients
were categorized by three levels: low (no recorded previ-
ous diseases), medium (1–2 points) and high (>2 points).
Statistical methods
We used linear regression models to study the association
between independent predictors and the dependent vari-
ables EQ-5D index and EQ VAS score. The regression co-
efficients were calculated with 95% confidence intervals,
which were used to describe statistical significance of as-
sociation. Age was investigated by a restricted cubic spline
to avoid residual confounding for the comorbidity vari-
ables. The number of knots on the spline curve was
chosen by selecting the model with the lowest Akaike in-
formation criterion [11]. Effect modification for country
was evaluated by ANOVA (analysis of variance).
All analyses where performed using R version 3.0.1,
and the rms package (v 4.0-0). Due to non-normal dis-
tributed outcomes with heteroscedasticity the confidence
intervals were calculated by using a robust covariance
matrix (HC3) [12,13].
Ethical approval
Ethical review approval was obtained from the Central
Ethical Review Board in Gothenburg for the merger of
the SHAR with the Swedish National Patient Register
(decision 328–08) databases, and by amendment the
merging of the populations from SHAR and DHR (de-
cision T210-12). The merger of the DHR and Danish
National Registry of Patients was approved by the




As presented in Table 1, the demography and comorbid-
ity burden was similar in the two populations. There
were no or minor disparities in the demography and co-
morbidity burden compared to the THR populationsedish and Danish patients. Forest plot with 95% confidence intervals
female), age 85 years (reference=65 years), and medium or high
ents.
Figure 2 Comparison of factors influencing EQ VAS between Swedish and Danish patients. Forest plot with 95% confidence intervals for
the estimates of EQ VAS one year after THR for gender (reference=female), age 85 years (reference=65 years), and medium or high Charlson
(reference=low Charlson) for Swedish (blue) and Danish (red) patients.
Table 3 Association between possible independent
predictors and the mean value of EQ-5D index
Variable Crude Adjusted
Coef 2.5% to 97.5% Coef 2.5% to 97.5%
Intercept 0.815 0.812 to 0.818 0.800 0.759 to 0.841
Sex
Male 0 ref 0 ref
Female −0.042 −0.048 to −0.036 −0.040 −0.046 to −0.034
Charlson’s index
Low 0 ref 0 ref
Medium (1–2) −0.043 −0.052 to −0.034 −0.039 −0.048 to −0.030
High (> 2) −0.093 −0.123 to −0.062 −0.092 −0.123 to −0.062
Denmark
Country = Sweden −0.041 −0.056 to −0.026 −0.039 −0.054 to −0.024
Adjusted results refer to the full model with all predictors in the table and the
spline for age.
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periods (Table 1).
Main results - comparison between countries
Danish patients had an overall higher EQ-5D index and
EQ VAS than Swedish patients (p < 0.001). The distribu-
tion of answers in the five EQ-5D dimensions signifi-
cantly (all p < 0.001) differed between countries; Danish
patients scored higher for the mobility, pain/discomfort,
and anxiety/depression qualities, while Danish patients
scored lower in the usual activities dimension (Table 2).
There was no difference between the countries in how
sex, age or the Charlson comorbidity index affected the
EQ-5D index (p = 0.83) or EQ VAS (p = 0.41) one year
after hip replacement (Figures 1 and 2).
Other results - identification of overall predictors for PRO
Male patients reported higher EQ-5D indexes and EQ
VAS scores than females. Patients with a medium or
high Charlson comorbidity index at the time of primary
THR surgery reported poorer outcomes for the EQ-5D
index and EQ VAS compared to patients with low
Charlson comorbidity index (Tables 3 and 4). Age be-
haved in a non-linear pattern, peaking at around 65 years
(Figures 3 and 4).
Discussion
In this study of patients with THR in Denmark and
Sweden, we found no significant differences in how age,
sex and comorbidity status influence the level of HRQoL
one year after surgery. The consistency of these common
and basic predictors facilitates pooling and comparisons of
data and interpretation of results from the two countries.
Comparisons between countries
Continual development in joint replacement surgery, con-
tinual progresses in medicine, and longer life expectancy,
have led to increasing demands for joint replacements.
Today there are numerous long-term reports documenting
the outstanding survival of many implant designs. Onefundamental prerequisite for understanding how to meet
the changes in demands on joint replacement surgery is to
measure outcomes from a patient perspective. PROMs are
becoming increasingly important in the allocation of health
care resources and the provision of guidelines for optimum
care and management [14]. Large variations between and
within countries in disease severity when deciding to oper-
ate have been reported [15]. How these variations affect
the PROs is sparsely explored. Therefore, in order to com-
pare PROs between countries, these common covariates
need to be investigated and compared.
Why Danish patients report higher HRQoL one year
postoperatively than Swedish is a question requiring
consideration. Firstly, population studies have shown
that Danish people in general perceive their HRQoL to
be higher than Swedes do [16,17]. Thus, the assumption
that EQ-5D values for Danish patients at any time-point
are higher than for Swedish patients, would partly ex-
plain the observed difference. Secondly, differences in
fixation method, implants used and surgical technique
may play a role for the PROs. Exempli gratia, the
Table 4 Association between possible independent
predictors and the mean value of EQ VAS
Variable Crude Adjusted
Coef 2.5% to 97.5% Coef 2.5% to 97.5%
Intercept 75.7 75.4 to 76.0 77.5 72.9 to 82.1
Sex
Male 0 ref 0 ref
Female −2.7 −3.4 to −2.1 −2.4 −3.1 to −1.8
Charlson’s index
Low 0 ref 0 ref
Medium (1–2) −5.8 −6.8 to −4.8 −5.1 −6.1 to −4.1
High (> 2) −13.8 −17.1 to −10.5 −13.1 −16.8 to −9.3
Denmark
Country = Sweden −6.1 −7.7 to −4.4 −5.7 −7.2 to −4.1
Adjusted results refer to the full model with the predictors in the table and
the spline for age.
Figure 4 The age as a spline for EQ VAS. The spline is adjusted
for sex = female, Charlson score = low, and country = Sweden.
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previous work indicates that a posterior approach is as-
sociated with better PROs as compared to the direct lat-
eral approach [18,19]. Thirdly, the difference in mean
age at surgery indicates that Danish patients have
surgery at an earlier stage of hip disease. Although age is
included in the regression model, there may be residual
confounding due to age being a proxy for stage of hip
disease. Surgery at an earlier stage of disease implies a
preservation of HRQoL after hip replacement. Conversely,
surgery at a late stage of disease may reduce the possibility
of reaching the expected level of HRQoL for the particular
age group. We do not believe the difference in recruitment
years explains the observed difference. This view isFigure 3 The age as a spline for EQ-5D index. The spline is adjusted
for sex = female, Charlson score = low, and country = Sweden.supported by the consistency in the EQ-5D index over
time in the Swedish THR population.
Age as a predictor
The one-year level of EQ-5D index peaks at about 65 to
70 years. The gradual decline in ages above 70 could be
explained by the overall age-dependent abatement seen
in the general population. However, the youngest pa-
tients did not reach the expected level of EQ-5D. Our
interpretation is that younger patients have more active
lifestyles and are more likely to be hampered by the limi-
tations of their hip disease, and subsequently their artifi-
cial joint, than older patients. The lower mean EQ-5D
index in younger patients suggests room for improve-
ment in the way these patients are managed. In order to
preserve as much HRQoL as possible among younger
patients, persevering with non-surgical treatment op-
tions is important. However, it might reasonably be ar-
gued that they should have surgery at an earlier stage,
and yet the risk of revision complicates this analysis.
Methodological considerations
The large study population combining a nationwide
Swedish THR population and a randomly selected na-
tionwide Danish THR population contributes to the
strength of this study. Reoperations have been excluded
which limits the effect of potential confounders related
to implant survival.
The cross-sectional nature of the study limits compari-
sons of outcomes between the two countries and few
variables have been included in the models. Preoperative
PROMs were not available for the Danish patients and
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were not possible. Furthermore, the Danish population
was much smaller than the Swedish and chance may
affect Danish data to a greater extent than Swedish.
Including a larger Danish population may have resulted
in significant differences between countries in how the
investigated predictors affect the outcomes. However,
the clinical relevance of such small differences would, in
that case, be questioned.Conclusions
There are clear similarities in how basic predictors influ-
ence patient-reported outcomes in patients with THR in
Sweden and Denmark. Apparent cultural, social and other
such differences among these countries are not reflected
in these predictors. However, Danish THR patients exhibit
a significantly higher HRQoL one year after surgery com-
pared to Swedish patients. This difference will be subject
to further analyses of prospective data.
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